Personalized medicine in warfarin therapy

Feb 25, 2010

Researchers from the Ohio State University have developed a rapid, multiplexed genotyping method to identify the single nucleotide polymorphisms (SNPs) that affect warfarin dose. The related report by Yang et al, "Rapid Genotyping of SNPs Influencing Warfarin Drug Response by SELDI-TOF Mass Spectrometry," appears in the March 2010 issue of the Journal of Molecular Diagnostics.

Warfarin is an anti-coagulant that is commonly used to prevent blood clots and embolism. However, warfarin dosing is complicated by the fact that it interacts with many commonly used medications and even chemicals in some foods. Certain genetic variations, SNPs, also affect warfarin sensitivity and metabolism.

A group led by Dr. Haifeng M. Wu of the Ohio State University has developed a new rapid method to genotype SNPs that will help clinicians to choose appropriate doses of warfarin for individual patients. Using surface-enhanced laser desorption and ionization time-of-flight (SELDI-TOF MS), which can determine the elemental composition of a sample, Yang et al could determine the genotype of three warfarin-related SNPs in under five hours with high levels of accuracy.

Yang et al suggest that "on-site application of this method in hospital laboratories will greatly help clinicians to determine appropriate doses of to treat patients with thromboembolic disorders." In future studies, Dr Wu and colleagues plan to apply the SELDI-TOF platform to genotype other medically important SNPs that influence the efficacy and safety profiles of many drug therapies and ultimately to promote personalized health care at Ohio State University .

Explore further: Dislocations in oxides seen as promising electrolytes create a 'traffic jam' for charged ions

More information: Yang S, Xu L, Wu HM: Rapid Genotyping of SNPs Influencing Warfarin Drug Response by SELDI-TOF Mass Spectrometry. J Mol Diagn 2010, 162-168.

add to favorites email to friend print save as pdf

Related Stories

Genetics determine optimal drug dose of common anticoagulant

Aug 21, 2007

Genetic testing can be used to help personalize the therapeutic dosage of warfarin, a commonly-used anticoagulant, according to research published in the September 1, 2007, issue of Blood, the journal of the American Societ ...

Kidney disease affects response to blood thinner

Feb 18, 2009

Patients with reduced kidney function require lower doses of the anticoagulant drug warfarin, and may need closer monitoring to avoid serious bleeding complications, suggests a study in the April 2009 issue of the Journal of ...

Right warfarin dose determined by 3 genes

Mar 20, 2009

Researchers at Uppsala University, together with colleagues at the Karolinska Institute and the Sanger Institute, have now found all the genes the determine the dosage of the blood-thinning drug warfarin. The findings are ...

Recommended for you

Scientists find clues to cancer drug failure

17 hours ago

Cancer patients fear the possibility that one day their cells might start rendering many different chemotherapy regimens ineffective. This phenomenon, called multidrug resistance, leads to tumors that defy ...

Smart crystallization

22 hours ago

A novel nucleating agent that builds on the concept of molecularly imprinted polymers (MIPs) could allow crystallographers access to proteins and other biological macromolecules that are usually reluctant ...

Supersonic electrons could produce future solar fuel

22 hours ago

Researchers from institutions including Lund University have taken a step closer to producing solar fuel using artificial photosynthesis. In a new study, they have successfully tracked the electrons' rapid transit through ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.